Sol-Gel Technologies: SGT-610 Holds Billion-Dollar Potential in Gorlin Syndrome – Mizuho Recommends Buy

Mizuho initiates Coverage: The investment bank has initiated coverage on Sol-Gel Technologies with an "Outperform" rating and a price target of $285. Focus on SGT-610: The topical Hedgehog inhibitor is considered a potential "First-in-Class" FDA-approved therapy for the prevention of basal cell carcinomas in patients with Gorlin syndrome. Billion-Dollar Market in Sight: Analysts forecast a peak revenue potential of around $1 billion for the drug. Strategic Realignment in Business Model Sol-Gel Technologies (SLGL) operates as a clinical-stage...